You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

 

Online download statistics by month:

Online download statistics by month: March 2021 to July 2025

AbstractFullPdf
Mar 2021511510252
Apr 2021228228124
May 202114814839
Jun 202113413427
Jul 202112712740
Aug 202113113134
Sep 202110810844
Oct 202114614652
Nov 202114114066
Dec 202117718352
Jan 202215716357
Feb 2022758322
Mar 202212813856
Apr 2022949944
May 202230130973
Jun 202210510855
Jul 202210010647
Aug 202214515290
Sep 202214114286
Oct 202214415176
Nov 202214314965
Dec 202214114255
Jan 202314514589
Feb 202316817168
Mar 2023263267100
Apr 202315315772
May 202314114654
Jun 202314214863
Jul 202312312348
Aug 202314314444
Sep 202324324679
Oct 202336736846
Nov 202354955328
Dec 202319219751
Jan 2024100101216
Feb 202414514645
Mar 202417017469
Apr 202416015945
May 2024818230
Jun 202412212338
Jul 202414314431
Aug 202410910832
Sep 202412913848
Oct 202414714966
Nov 202416817184
Dec 202422423079
Jan 202515515578
Feb 202517617878
Mar 202511011149
Apr 202516916970
May 202518618787
Jun 202513013154
Jul 2025220
Total878089203397